FDA Advisers Approve Carvykti and Abecma for Earlier Treatment Options
Washington, D.C. – An FDA advisory panel has recommended the approval of two groundbreaking cancer treatments, Carvykti and Abecma, for use in earlier stages of the disease. This decision comes despite initial concerns about potential risks associated with the treatments. Carvykti, developed by J&J and Legend, and Abecma, developed by BMS, have shown promising results … Read more